Spanish dermatology-focused pharma Almirall (BME: ALM) reported full-year 2025 net sales of 1.1 billion euros ($1.2 billion), ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial ...

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial executi ...

Atopic dermatitis, also known as eczema, is a chronic, inflammatory skin condition characterized by intense itching, dry skin, and recurrent flare-ups of red, inflamed lesions. It is driven by a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Please provide your email address to receive an email when new articles are posted on . “Clinician awareness of atopic comorbidities and the additional impact that these conditions have on patients ...

Almirall, S.A. (ALM), a global pharmaceutical company dedicated to medical dermatology, announces the planned start of a phase III study assessing the efficacy and safety of Lebrikizumab (Ebglyss ®, ...

Exposure to higher levels of air pollution as a baby is linked to having a peanut allergy throughout childhood, according to a new study. And policies aimed at tackling poor air quality could ...

Johnson & Johnson said on Friday it discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis after it failed to meet efficacy goals in an ...